secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-134769
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q1 net loss $31.6M; cash $180.9M; pipeline milestones on track
--------------------------------------------------------------------------------

- Q1 revenue $12.5M (vs $12.9M YoY); net loss $31.6M (vs $27.4M). Cash $180.9M; plus $12M from GSK milestone in April.
- RestorAATion-2 for AATD underway; proof-of-mechanism data expected in 2024.
- INHBE obesity program targets 1Q 2025 trial start; preclinical weight loss similar to semaglutide with fat loss, no muscle loss.
- FORWARD-53 DMD 24-week dystrophin data expected 3Q 2024; SELECT-HD multi-dose data expected 2Q 2024.
- Appointed Dr. Erik Ingelsson as CSO to drive genetic target discovery; GSK advanced two programs triggering $12M payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524134769/0001193125-24-134769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524134769/d813742d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-134769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer